Spanlecortemlocel

N/A

Report date: 2025/03/14 13:17:36

Base Information

Drug NameSpanlecortemlocel
Drug Alias NameExpanded umbilical cord bloodLFU835 expanded umbilical cord blood stem cellsCord blood stem cell therapyMGTA-456HSC-835
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derived
Mechanisms of ActionStem cell replacementsAryl hydrocarbon receptor antagonists
TargetsAryl hydrocarbon receptor
Therapy Area/IndicationsMetabolic DiseasesMyelodysplastic SyndromesWaldenstrom Macroglobulinemia +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota
Inactive CompaniesMagenta Therapeutics IncNovartis Pharma Ag
Active IndicationsMyelodysplastic SyndromesWaldenstrom MacroglobulinemiaLymphoma, T-Cell +[9] 
Inactive IndicationsMetabolic DiseasesMultiple MyelomaLymphoma, Large-Cell, Anaplastic +[7] 

Other Information

ATC CodeN/A
Related LinksN/A